GH1 and acromegaly: To gain more insight into the mechanism of action of pasireotide in patients with acromegaly inadequately controlled with first-generation somatostatin analogues, changes in the clinically established efficacy biomarkers GH and IGF-1, as well as other biomarkers (IGF-binding protein [IGFBP]-2/3, glucose and glycated haemoglobin [HbA1c]), were assessed after pasireotide LAR treatment.